Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:43 2025-07-08 am EDT			After hours 11:20:00 am
449.95 ^DKK	+1.98%		449.95	0.00%

11:00am	Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	RE
10:21am	WeightWatchers names new medical chief, plans to offer menopause therapy and support	RE

Novo Nordisk Says Planning To Initiate A Phase 3 Development Programme With Amycretin For Adults With Overweight Or Obesity During Q1 Of 2026

Published on 06/12/2025 at 13:12

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	11:00am	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	10:21am	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	09:50am	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	09:50am	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	09:33am	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	09:27am	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	09:23am	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	09:20am	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	06:45am	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	Jul. 07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	Jul. 07	RE
The importance of being constantly changing…	Jul. 07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	Jul. 04	FW
SAP Becomes Europe's Most Valuable Company as Nvidia Leads Globally	Jul. 03	RE
NOVO NORDISK : UBS reiterates its Buy rating	Jul. 03	ZD
Ascletis Pharma Begins Dosing Subjects in US Weight Management Drug Study; Shares Gain 3%	Jul. 02	MT
How did Novo Nordisk lose the US market?	Jul. 02
Novo Nordisk, WeightWatchers Expand Collaboration for Enhanced Access to Wegovy	Jul. 01	MT
WW International, Inc. and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care	Jul. 01	CI
How Novo Nordisk misread the US market for its weight loss sensation	Jul. 01	RE
How Novo Nordisk misread the US market for its weight loss sensation	Jul. 01	RE
Sector Update: Health Care Stocks Advance Tuesday Afternoon	Jul. 01	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

Aug. 06 - Q2 2025 Earnings Release

More about the company